Floatz logo

Autologous Bcma/Gprc5D Dual-Target Car-T

BPDCN; Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia

Beijing BiotechCell therapyPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

79 Active assets in the BPDCN; Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Children's Oncology Group
Phase 3BB
PEGASPARGASE
Children's Oncology Group
Phase 3BB
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
University of Washington
Phase 3BB
MERCAPTOPURINE ANHYDROUS
SWOG Cancer Research Network
Phase 3BB
Daunorubicin
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

Autologous Bcma/Gprc5D Dual-Target Car-T is also rated in:

B-cell acute lymphoblastic leukemiaDormant
CC
Indicative ·
47 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →